Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:CIT-SPPL3

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: CIT-SPPL3
	FusionPDB ID: 16873
	FusionGDB2.0 ID: 16873
		Hgene	Tgene
	Gene symbol	CIT	SPPL3
	Gene ID	79947	121665
	Gene name	dehydrodolichyl diphosphate synthase subunit	signal peptide peptidase like 3
	Synonyms	CIT\|CPT\|DEDSM\|DS\|HDS\|RP59\|hCIT	IMP2\|MDHV1887\|PRO4332\|PSH1\|PSL4
	Cytomap	1p36.11	12q24.31
	Type of gene	protein-coding	protein-coding
	Description	dehydrodolichyl diphosphate synthase complex subunit DHDDScis-IPTasecis-isoprenyltransferasecis-prenyl transferasecis-prenyltransferase subunit hCITdedol-PP synthasedehydrodolichyl diphosphate syntase complex subunit DHDDSepididymis tissue protein	signal peptide peptidase-like 3SPP-like 3intramembrane protease 2presenilin homologous protein 1presenilin-like protein 4
	Modification date	20200313	20200313
	UniProtAcc	Q96RK1 Main function of 5'-partner protein: FUNCTION: Acts as transcriptional coactivator for TFAP2/AP-2. Enhances estrogen-dependent transactivation mediated by estrogen receptors. May function as an inhibitor of transactivation by HIF1A by disrupting HIF1A interaction with CREBBP. May be involved in regulation of gene expression during development and differentiation of blood cells, endothelial cells and mammary epithelial cells. {ECO:0000269\|PubMed:11744733, ECO:0000269\|PubMed:15342390}.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000537607, ENST00000261833, ENST00000392521,	ENST00000353487,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	9 X 9 X 6=486	11 X 9 X 5=495
	# samples	9	11
	** MAII score	log2(9/486*10)=-2.43295940727611 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(11/495*10)=-2.16992500144231 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: CIT [Title/Abstract] AND SPPL3 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: CIT [Title/Abstract] AND SPPL3 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	CIT(120189855)-SPPL3(121204175), # samples:1
Anticipated loss of major functional domain due to fusion event.	CIT-SPPL3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. CIT-SPPL3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. CIT-SPPL3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. CIT-SPPL3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	CIT	GO:0006489	dolichyl diphosphate biosynthetic process	28842490
Tgene	SPPL3	GO:0033619	membrane protein proteolysis	2313285

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr12:120189855/chr12:121204175)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across CIT (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across SPPL3 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000392521	CIT	chr12	120189855	-	ENST00000353487	SPPL3	chr12	121204175	-	5631	2960	26	3067	1013
ENST00000261833	CIT	chr12	120189855	-	ENST00000353487	SPPL3	chr12	121204175	-	5502	2831	23	2938	971

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000392521	ENST00000353487	CIT	chr12	120189855	-	SPPL3	chr12	121204175	-	0.001491922	0.99850804
ENST00000261833	ENST00000353487	CIT	chr12	120189855	-	SPPL3	chr12	121204175	-	0.002184587	0.9978154

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for CIT-SPPL3

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
CIT	chr12	120189855	SPPL3	chr12	121204175	2831	936	TTAEAEEEIQALTACSLLLWRLAFTG
CIT	chr12	120189855	SPPL3	chr12	121204175	2960	978	TTAEAEEEIQALTACSLLLWRLAFTG

Top

Potential FusionNeoAntigen Information of CIT-SPPL3 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

CIT-SPPL3_120189855_121204175.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B45:01	EEIQALTA	0.9997	0.8832	6	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B50:02	EEIQALTA	0.9997	0.6666	6	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B57:01	TACSLLLW	0.9996	0.9927	12	20
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B58:02	TACSLLLW	0.9993	0.9905	12	20
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B58:01	TACSLLLW	0.9987	0.9895	12	20
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B18:01	EEIQALTA	0.9858	0.7997	6	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B41:01	EEIQALTA	0.9742	0.9154	6	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B50:01	EEIQALTA	0.9526	0.7371	6	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B58:01	LTACSLLLW	0.999	0.9909	11	20
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B57:01	LTACSLLLW	0.9988	0.9945	11	20
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B58:02	LTACSLLLW	0.9976	0.991	11	20
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B15:17	LTACSLLLW	0.9958	0.988	11	20
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B45:01	EEEIQALTA	0.995	0.909	5	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B15:16	LTACSLLLW	0.9918	0.9844	11	20
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B57:03	LTACSLLLW	0.9813	0.9982	11	20
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B45:01	EEIQALTAC	0.979	0.9106	6	15
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B50:02	EEIQALTAC	0.9653	0.6133	6	15
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B50:02	EEEIQALTA	0.9544	0.6984	5	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B48:01	IQALTACSL	0.912	0.5322	8	17
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B18:01	EEIQALTAC	0.7378	0.6914	6	15
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B41:01	EEEIQALTA	0.6425	0.864	5	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B13:01	IQALTACSL	0.4144	0.9618	8	17
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B50:01	EEEIQALTA	0.3653	0.7418	5	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B41:01	EEIQALTAC	0.2782	0.8409	6	15
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B50:01	EEIQALTAC	0.1211	0.7479	6	15
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B45:01	AEEEIQALTA	0.9972	0.9393	4	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B57:01	ALTACSLLLW	0.9959	0.9938	10	20
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B50:02	AEEEIQALTA	0.9923	0.7583	4	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B50:01	AEEEIQALTA	0.8546	0.8548	4	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B41:01	AEEEIQALTA	0.8013	0.8915	4	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B57:01	QALTACSLLLW	0.999	0.9932	9	20
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B58:01	QALTACSLLLW	0.9941	0.9895	9	20
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B58:02	QALTACSLLLW	0.9934	0.9885	9	20
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B57:03	QALTACSLLLW	0.9686	0.9977	9	20
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B40:06	EEIQALTA	0.9996	0.5385	6	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B40:06	EEIQALTAC	0.9422	0.5555	6	15
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B40:06	AEEEIQALTA	0.9941	0.7246	4	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B44:10	EEIQALTACSL	0.9967	0.5484	6	17
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B57:10	TACSLLLW	0.9996	0.9927	12	20
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B18:06	EEIQALTA	0.9864	0.8471	6	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B18:05	EEIQALTA	0.9858	0.7997	6	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B18:03	EEIQALTA	0.9769	0.7891	6	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B50:04	EEIQALTA	0.9526	0.7371	6	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B50:05	EEIQALTA	0.9526	0.7371	6	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B57:04	LTACSLLLW	0.9993	0.9557	11	20
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B57:10	LTACSLLLW	0.9988	0.9945	11	20
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B57:02	LTACSLLLW	0.9976	0.991	11	20
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B58:06	LTACSLLLW	0.9947	0.9891	11	20
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B15:73	IQALTACSL	0.8707	0.9622	8	17
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B39:02	IQALTACSL	0.8051	0.9446	8	17
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B15:30	IQALTACSL	0.7917	0.8848	8	17
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B18:08	EEIQALTAC	0.7387	0.7974	6	15
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B18:05	EEIQALTAC	0.7378	0.6914	6	15
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B18:06	EEIQALTAC	0.6776	0.7063	6	15
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B18:03	EEIQALTAC	0.6635	0.679	6	15
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B50:04	EEEIQALTA	0.3653	0.7418	5	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B50:05	EEEIQALTA	0.3653	0.7418	5	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B15:09	IQALTACSL	0.3449	0.7808	8	17
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B50:05	EEIQALTAC	0.1211	0.7479	6	15
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B50:04	EEIQALTAC	0.1211	0.7479	6	15
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B57:04	ALTACSLLLW	0.9983	0.9535	10	20
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B57:10	ALTACSLLLW	0.9959	0.9938	10	20
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B50:05	AEEEIQALTA	0.8546	0.8548	4	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B50:04	AEEEIQALTA	0.8546	0.8548	4	14
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B57:10	QALTACSLLLW	0.999	0.9932	9	20
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B57:04	QALTACSLLLW	0.998	0.9247	9	20
CIT-SPPL3	chr12	120189855	chr12	121204175	2831	HLA-B57:02	QALTACSLLLW	0.987	0.9933	9	20

Top

Potential FusionNeoAntigen Information of CIT-SPPL3 in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of CIT-SPPL3

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
1669	EEIQALTACSLLLW	CIT	SPPL3	chr12	120189855	chr12	121204175	2831

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of CIT-SPPL3

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	1669	EEIQALTACSLLLW	-7.42554	-7.62604
HLA-B14:02	3BVN	1669	EEIQALTACSLLLW	-5.77656	-6.53696
HLA-B52:01	3W39	1669	EEIQALTACSLLLW	-7.78174	-7.98224
HLA-B52:01	3W39	1669	EEIQALTACSLLLW	-6.37638	-7.13678
HLA-A11:01	4UQ2	1669	EEIQALTACSLLLW	-8.61504	-8.81554
HLA-A11:01	4UQ2	1669	EEIQALTACSLLLW	-7.13801	-7.89841
HLA-A24:02	5HGA	1669	EEIQALTACSLLLW	-7.96784	-8.16834
HLA-A24:02	5HGA	1669	EEIQALTACSLLLW	-5.51423	-6.27463
HLA-B44:05	3DX8	1669	EEIQALTACSLLLW	-5.28239	-6.04279
HLA-B44:05	3DX8	1669	EEIQALTACSLLLW	-4.26556	-4.46606

Top

Vaccine Design for the FusionNeoAntigens of CIT-SPPL3

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
CIT-SPPL3	chr12	120189855	chr12	121204175	10	20	ALTACSLLLW	GCACTCACGGCCTGCTCACTGCTACTGTGG
CIT-SPPL3	chr12	120189855	chr12	121204175	11	20	LTACSLLLW	CTCACGGCCTGCTCACTGCTACTGTGG
CIT-SPPL3	chr12	120189855	chr12	121204175	12	20	TACSLLLW	ACGGCCTGCTCACTGCTACTGTGG
CIT-SPPL3	chr12	120189855	chr12	121204175	4	14	AEEEIQALTA	GCTGAAGAGGAGATCCAGGCACTCACGGCC
CIT-SPPL3	chr12	120189855	chr12	121204175	5	14	EEEIQALTA	GAAGAGGAGATCCAGGCACTCACGGCC
CIT-SPPL3	chr12	120189855	chr12	121204175	6	14	EEIQALTA	GAGGAGATCCAGGCACTCACGGCC
CIT-SPPL3	chr12	120189855	chr12	121204175	6	15	EEIQALTAC	GAGGAGATCCAGGCACTCACGGCCTGC
CIT-SPPL3	chr12	120189855	chr12	121204175	6	17	EEIQALTACSL	GAGGAGATCCAGGCACTCACGGCCTGCTCACTG
CIT-SPPL3	chr12	120189855	chr12	121204175	8	17	IQALTACSL	ATCCAGGCACTCACGGCCTGCTCACTG
CIT-SPPL3	chr12	120189855	chr12	121204175	9	20	QALTACSLLLW	CAGGCACTCACGGCCTGCTCACTGCTACTGTGG

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of CIT-SPPL3

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
UCEC	CIT-SPPL3	chr12	120189855	ENST00000261833	chr12	121204175	ENST00000353487	TCGA-E6-A8L9-01A

Top

Potential target of CAR-T therapy development for CIT-SPPL3

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Tgene

SPPL3

chr12:120189855

chr12:121204175

ENST00000353487

340_360

385.0

Transmembrane

Helical

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to CIT-SPPL3

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to CIT-SPPL3

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)